公开(公告)号：NZ514171A

公开(公告)日：2003-10-31

申请号：NZ51417197

申请日：1997-02-12

Applicant: ABBOTT LAB

Inventor： WINN MARTIN ,  BOYD STEVEN A ,  HUTCHINS CHARLES W ,  JAE HWAN SOO ,  TASKER ANDREW S ,  VON GELDERN THOMAS V ,  KESTER JEFFREY A ,  SORENSEN BRYAN K ,  SZCZEPANKIEWICZ BRUCE G ,  ENRY KENNETH J ,  LIU GANG ,  WITTENBERGER STEVEN J ,  KING STEVEN A

IPC: A61P9/10 ,  A61P9/12 ,  C07D405/04 ,  C07F9/572 ,  A61K3 ,  C07D20 ,  C07D40

Abstract: Compounds a) (2R, 3R, 4S)-2-(3-Fluoro-4methoxyphenyl)-4-(1.3- benzodioxol-5-yl)-1-(2-(N-propyl-N- pentanesulfonylamino)ethyl)-pyrrolidine-3-carboxylic acid b) trans, trans-2-(2,2-Dimethylpentyl)-4-(7-methoxy-1,3- benzodioxol-5-yl)-1-(N,N-dibutylaminocarbonylmethyl)- pyyrolidine-3-carboxylic acid c) trans, trans-2-(4-Methoxyphenyl)-4-(1,3-benzodioxol-5- yl)-1-[(N-butyl-N-(4- dimethylaminobutyl)amino)carbonylmethyl]-pyyrolidine-3- carboxylic acid The uses of the compounds may include antagonsing endothelin in a mammal, treating - hypertension, congestive heart failure, restenosis following arterial injury, cerebral ischemia, myocardial ischemia, atherosclerosis, angina, cerebral vasospasm, a LPL-related lipoprotein disorder, Raynaud's disease, nociception and cancer.